NCT04722887: An ongoing trial by Grifols Therapeutics LLC
This trial is ongoing. It must report results 8 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04722887 |
|---|---|
| Title | A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% Administered Subcutaneously in Subjects With Alpha1-Antitrypsin Deficiency |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 13, 2021 |
| Completion date | July 17, 2025 |
| Required reporting date | July 17, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 27, 2025 |
| Days late | None |